The significance of immunology in orthopaedics today;Aktueller stand der immunologie in der orthopädie

Orthopade

Volumn 32, Issue 8, 2003, Pages 736-743

  Veihelmann, A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Immunology; Immunomodulation; Inflammation; Orthopaedics

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIRHEUMATIC AGENT; ETANERCEPT; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR; METHOTREXATE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ARTICLE; BONE TUMOR; DRUG EFFICACY; DRUG TOLERABILITY; ENDOPROSTHESIS; ENZYME ACTIVITY; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFLAMMATION; METHODOLOGY; ORTHOPEDICS; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; SAFETY; TUMOR IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOTHERAPY; ORTHOPEDICS; OSTEOARTHRITIS;

EID: 0141457575     PISSN: 00854530     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00132-002-0420-z     Document Type: Article

References (98)

1. Al-Saffar N (1999) The osteogenic properties of the interface membrane at the site of orthopedic implants: the impact of underlying joint disease. J Long Term Eff Med Implants 9: 23-45
2. Al-Saffar N, Mah J, Kadoya Y, Revell PA (1995) Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants. Ann Rheum Dis 54: 201-208
3. Al-Saffar N, Revell PA. (1999) Pathology of the bone-implant interface. J Long Eff Med Implants 9: 319-347
4. Antoni C, Kalden JR (1999) Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 17: 73-77
5. Bathon JM, Martin RW, Fleischmann RM et al. (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343: 1586-1593
6. Ben-Efraim S (1996) Cancer immunotherapy: hopes and pitfalls: a review, Anticancer Res 16: 3235-3240
7. Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18: 267-268
8. Bresnihan B (1999) Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann Rheum Dis 58 [Suppl 1]: 196-198
9. Catelas I, Petit A, Zukor DJ, Marchand R, Yahia L, Huk OL (1999) Induction of macrophage apoptosis by ceramic and polyethylene particles in vitro. Biomaterials 20: 625-630
10. Davis TA, Grillo-Lopez AJ, White CA et al. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18: 3135-3143
11. de Mello SB, Novaes GS, Laurindo IM, Muscara MN, Maciel FM, Cossermelli W (1997) Nitric oxide synthase inhibitor influences prostaglandin and interleukin-1 production in experimental arthritic joints. Inflamm Res 46: 72-77
12. De Plaen E, Lurquin C, Lethe B et al. (1997) Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods 12: 125-142
13. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991
14. Dinarello CA (2000) The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 343: 732-734
15. Ergun S, Kilic N, Fiedler W, Mukhopadhyay AK (1997) Vascular endothelial growth factor and its receptors in normal human testicular tissue. Mol Cell Endocrinol 131: 9-20
16. Fava RA, Olsen NJ, Spencer GG, Yeo KT et al. (1994) Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180: 341
17. Feige U, Hu YL, Gasser J, Campagnuolo G, Munyakazi L, Bolon B (2000) Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life 57: 1457-1470
18. Feige U, Hu YL, Gasser J, Campagnuolo G, Munyakazi L, Bolon B (2000) Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life 57: 1457-1470
19. Fenner H. (1998) Immunpharmakologisches Profil und therapeutische Perspektiven von anti-TNF alpha-Therapien. Z Rheumatol 57: 294-297
20. Fenner H (1998) Immunpharmakologisches Profil und therapeutische Perspektiven von anti-TNF alpha-Therapien. Z Rheumatol 57: 294-297
21. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25
22. Fletcher DS, Widmer WR, Luell S, Christen A, Orevillo C, Shah S, Visco D (1998) Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats. J Pharmacol Exp Ther 284: 714-721
23. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27
24. Forre O, Haugen M, Hassfeld WG (2000) New treatment possibilities in rheumatoid arthritis. Scand J Rheumatol 29: 73-84
25. Glennie MJ, Johnson PWM (2000) Clinical trials of antibody therapy. Immunol Rev 21: 403-410
26. Goldenberg MM (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21: 309-318
27. Handy RL, Moore PK (1998) A comparison of the effects of L-NAME, 7-NI and L-NIL on carrageenan-induced hindpaw oedema and NOS activity. Br J Pharmacol 123: 1119-1126
28. Hobbs AJ, Higgs A, Moncada S (1999) Inhibition of nitric oxide synthase as a potential therapeutic target. Ann Rev Pharmacol Toxicol 39: 191-220
29. Inokuma S, Kono H, Nakayama H, Yamazaki J (2000) Immunoglobulin and lymphocyte decrease concurrent with adverse reactions induced by methotrexate for RA. Ann Rheum Dis 59: 495-496
30. Ishida H, Komiya S, Inoue Y, Yutani S, Inoue A, Itoh K (2000) Expression of the SART1 tumor-rejection antigen in human osteosarcomas. Int J Oncol 17: 29-32
31. Jacobs JW, Van der Weide FR, Kruijsen MW (1994) Fatal cholestatic hepatitis caused by D-penicillamine. Br J Rheumatol 33: 770-773
32. Janssen NM, Genta MS (2000) The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 160: 610-619
33. Jarvis B, Faulds D (1999) Etanercept: a review of its use in rheumatoid arthritis. Drugs 57: 945-966
34. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43: 1001-1009
35. Jones RE, Moreland LW (1999) Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis 48: 1-4
36. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van den Berg WB (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 163: 5049-5055
37. Kanwar S, Kubes P (1995) Nitric oxide is an antiadhesive molecule for leukocytes. New Horiz 3: 93-104
38. Kaur H, Halliwell B (1994) Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett 350: 9-12
39. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309
40. Kennedy B, Rawstron A, Carter C, Ryan M, Speed K, Lucas G, Hillmen P (2002) Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99: 2245-2247
41. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844
42. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N (1994) Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152: 4149
43. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497
44. Kohn D, Plitz W (1995) Endoprothetik und Knochenreaktion. Orthopade 24: 409-415
45. Lichtenbeld HC, Ferarra N, Jain RK, Munn LL (1999) Effect of local anti-VEGF antibody treatment on tumor microvessel permeability. Microvasc Res 57: 357-362
46. Lipsky PE,van der Heijde DM, St Clair EW et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594-1602
47. List AF (2001) Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist 6 [Suppl 5]: 24-31
48. Lu J, Kasama T, Kobayashi K, Yoda Y, Shiozawa F, Hanyuda M, Negishi M, Ide H, Adachi M (2000) Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol 164: 5922-5927
49. Maloney W, Smith L, Schmalzried T, Chiba J, Huene D, Rubash H (1995) Isolation and characterization of wear particles generated in patients who have had failure of a hip arthroplasty without cement. J Bone Joint Surg Am 77: 1301-1310
50. Maloney W, Smith L, Schmalzried Th, Chiba J, Huene D, Rubash H (1995) Isolation and characterization of wear particles generated in patients who have had failure of a hip arthroplasty without cement. J Bone Joint Surg Am 77: 1301-1310
51. Markham A, Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59: 1341-1359
52. Matthews JB, Green TR, Stone MH, Wroblewski BM, Fisher J, Ingham E (2000) Comparison of the response of primary human peripheral blood mononuclear phagocytes from different donors to challenge with model polyethylene particles of known size and dose. Biomaterials 21: 2033-2044
53. McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie QW, Nathan CF, Wahl SM (1993) Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 178: 749-754
54. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E (2000) Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 80: 1195-1205
55. Mordenti J, Thomsen K, Licko V, Chen H, Meng YG, Ferrara N (1999) Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 27: 14-21
56. Murrell GA, Jang D, Williams RJ (1995) Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 206: 15-21
57. Nakamura N, Shino K, Natsuume T, Horibe S, Matsumoto N, Kaneda Y, Ochi T (1998) Early biological effect of in vivo gene transfer of platelet-derived growth factor (PDGF)-B into healing patellar ligament. Gene Ther 5: 1165-1170
58. Nakashima Y, Sun DH, Trindade M, Maloney W, Goodman S, Schurman D, Smith L (1999) Signaling pathways for tumor necrosis factor-α and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J Bone Joint Surg Am 81: 603-615
59. Nathan C (1997) Inducible nitric oxide synthase: what difference does it make? J Clin Invest 100: 2417-2423
60. O'Reilly MS, Boehm T, Shing Y et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285
61. Paleolog EM (1996) Angiogenesis: a critical process in the pathogenesis of RA - a role for VEGF? Br J Rheumatol 35: 917-919
62. Pandey R, Quinn J, Joyner C, Murray DW, Triffitt JT, Athanasou NA (1996) Arthroplasty implant biomaterial particle associated macrophages differentiate into lacunar bone resorbing cells. Ann Rheum Dis 55: 388-395
63. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P (1994) Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28: 34-39
64. Pozza M, Guerra M, Manzini E, Calza L (2000) A histochemical study of the rheumatoid synovium: focus on nitric oxide, nerve growth factor high affinity receptor, and innervation. J Rheumatol 27: 1121-1127
65. Rader CP, Sterner T, Jakob F, Schutze N, Eulert J (1999) Cytokine response of human macrophage-like cells after contact with polyethylene and pure titanium particles. J Arthroplasty 14: 840-848
66. Ridger VC, Pettipher ER, Bryant CE, Brain SD (1997) Effect of the inducible nitric oxide synthase inhibitors aminoguanidine and L-N6-(1-iminoethyl)lysine on zymosan-induced plasma extravasation in rat skin. J Immunol 159: 383-390
67. Rosenberg SA. (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380-384
68. Rosenberg SA (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant Interleukin-2 to patients with metastatic cancer. N Eng J Med 313: 1485-1492
69. Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, Saito I, Miyasaka N. (01995) Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 96: 2357-2363
70. Sewell KL, Trentham DE. (1993) Pathogenesis of rheumatoid arthritis. Lancet 341: 283-286
71. Simank HG, Manggold J, Sebald W, Ries R, Richter W, Ewerbeck V, Sergi C (2001) Bone morphogenetic protein-2 and growth and differentiation factor-5 enhance the healing of necrotic bone in a sheep model. Growth Factors 19: 247-257
72. Spiecker M, Darius H, Kaboth K, Hübner F, Liao JK (1998) Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J Leukoc Biol 63: 732-739
73. St Clair EW (1998) Nitric oxide - friend or foe in arthritis? J Rheumatol 25: 1451-1453
74. Stefanovic-Racic M, Meyers K, Meschter C, Coffey JW, Hoffman RA, Evans CH (1994) N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum 37: 1062-1069
75. Stefanovic-Racic M, Meyers K, Meschter C, Coffey JW, Hoffman RA, Evans CH (1995) Comparison of the nitric oxide synthase inhibitors methylarginine and aminoguanidine as prophylactic and therapeutic agents in rat adjuvant arthritis. J Rheumatol 22: 1922-1928
76. Stenger S, Thuring H, Rollinghoff M, Manning P, Bogdan C (1995) L-N6-(1-iminoethyl)-lysine potently inhibits inducible nitric oxide synthase and is superior to NG-monomethyl-arginine in vitro and in vivo. Eur J Pharmacol 294: 703-712
77. Stichtenoth DO, Frolich JC (1998) Nitric oxide and inflammatory joint diseases. Br J Rheumatol 37: 246-257
78. Sudo T, Kuramoto T, Komiya S, Inoue A, Itoh K (1997) Expression of MAGE genes in osteosarcoma. J Orthop Res 1S: 128-132
79. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579-1586
80. Thomas KA (1996) Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 271: 603
81. Tomazic-Jezic VJ, Merritt K, Umbreit TH (2001) Significance of the type and the size of biomaterial particles of phagocytosis and tissue distribution. J Biomed Mater Res 55: 523-529
82. Tosetti F, Ferrari N, De Flora S, Albini A (2002) Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16: 2-14
83. Toumbis A, Kronick J, Wooley P, Nasser S (1977) Total joint arthroplasty and the immune response. Sem Arthritis Rheum 27: 44-47
84. Trieb K, Lang S, Kotz R (2000) Heat-shock protein 72 in human osteosarcoma: T-lymphocyte reactivity and cytotoxicity. Pediatr Hematol Oncol 17: 355-364
85. Tsao PS, Buitrago R, Chan JR, Cooke JP (1996) Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation 94: 1682-1689
86. Tsuda N, Murayama K, Ishida H, Matsunaga K, Komiya S, Itoh K, Yamada A (2001) Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res 19: 346-351
87. Veihelmann A, Hofbauer A, Krombach F, Dorger M, Maier M, Refior HJ, Messmer K (2002) Differential function of nitric oxide in murine antigen-induced arthritis. Rheumatology 41: 509-517
88. Veihelmann A, Landes J, Hofbauer A, Dorger M, Refior HJ, Messmer K, Krombach F (2001) Exacerbation of antigen-induced arthritis in inducible nitric oxide synthase-deficient mice. Arthritis Rheum 44: 1420-1427
89. Vernon-Roberts D, Freeman M (1977) The tissue response to total joint replacement prostheses. In: Sawanson S, Freeman M (eds) The scientific basis of joint replacement. Pitman Medical, Tunbridge Wells, pp 86-129
90. Walsh DA, Pearson CI (2001) Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 3: 147-153
91. Wang A, Essner A, Stark C, Dumbleton JH (1996) Comparison of the size and morphology of UHMWPE wear debris produced by a hip joint simulator under serum and water lubricated conditions. Biomaterials 17: 865-871
92. Wang G, Dong Z, Xu G, Yang Z, Shou C, Wang N, Liu T (1998) The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. J Cancer Res Clin Oncol 124: 615-620
93. Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552: 61-85
94. Willert HG, Semlitsch M (1977) Reactions of the articular capsule to wear products of artificial joint prostheses. J Biomed Mater Res 11: 157-164
95. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93: 14765-14770
96. Zingarelli B, Cuzzocrea S, Szabo C, Salzman AL (1998) Mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol ExpTher 287: 1048-1055
97. Zingarelli B, Szabo C, Salzman AL (1999) Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut 45: 199-209
98. Zysk SP, Gebhard H, Refior HJ, Plitz W, Messmer K, Veihelmann A (2002) Inflammatorische Reaktion auf Abriebpartikel von Endoprothesen in vivo: Ein experimentelles Modell an der Maus. Orthopade (im Druck)